Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCRESAHA.114.305216 | DOI Listing |
Publication Analysis
Top Keywords
letter makkar
4
makkar article
4
article "cell
4
"cell therapy
4
therapy heart
4
heart failure
4
failure comprehensive
4
comprehensive overview
4
overview experimental
4
experimental clinical
4
Similar Publications
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.
EuroIntervention
May 2024
Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Article Synopsis
- Some doctors suggest giving patients with a high bleeding risk a shorter treatment of medication after getting a special type of heart stent.
- This study looked at how safe and effective 1 month of this medication is compared to 3 months for patients who also had a type of heart problem or not.
- They found that 1-month treatment had the same chance of serious heart issues as the 3-month treatment, but it caused less bleeding after a year.
Anticoagulation for Atrial Fibrillation in Patients With Surgically Occluded Left Atrial Appendage.
J Am Coll Cardiol
May 2024
Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Increased CT angiography-derived extracellular volume fraction predicts less benefit in left ventricular remodeling and ejection fraction after transcatheter edge to edge repair for severe mitral regurgitation.
J Cardiovasc Comput Tomogr
March 2024
Mark Taper Imaging Center, Cedars Sinai Medical Center, Los Angeles, CA, USA; Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA. Electronic address:
1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program.
Am J Cardiol
March 2024
Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:
Article Synopsis
- The analysis evaluated the impact of 1-month versus 3-month dual antiplatelet therapy (DAPT) in older patients after percutaneous coronary intervention (PCI), focusing on those with high bleeding risk.
- In a study of 3,364 patients, they found similar rates of all-cause death or myocardial infarction for both therapy durations, regardless of whether patients were ≥75 years or <75 years old.
- However, patients aged ≥75 experienced significantly less bleeding with the 1-month DAPT compared to the 3-month treatment, suggesting a clearer benefit in reducing bleeding risk without increasing heart-related complications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!